Literature DB >> 10531241

Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice.

S Kawabata1, Y Terao, T Fujiwara, I Nakagawa, S Hamada.   

Abstract

For the development of vaccines against oral and pharyngeal pathogens invading the mucosal epithelia, both secretory and serum immunoglobulin A (IgA) and IgG antibodies and cytotoxic T lymphocytes (CTL) have been induced. We used a novel approach, targeted salivary gland (TSG) immunization, using plasmid pcDNA3/fimA, coding for Porphyromonas gingivalis fimbriae. Expression of subunit protein, fimbrillin, was observed in eukaryotic cells growing in vitro following transfection with pcDNA3/fimA. In this study, we obtained good humoral and cell-mediated immune responses in BALB/c mice by TSG administration using the above-mentioned DNA vaccine. The production of fimbria-specific IgA and IgG antibodies in saliva and serum IgG antibody was significantly stimulated by TSG immunization. Injection of DNA vaccine into salivary gland elicited high-level production of antigen-specific IgG antibody, similar to that induced following intramuscular immunization. The major IgG subclass that recognized fimbriae was IgG2a in serum from pcDNA3/fimA-immunized mice. Reverse transcription-PCR analysis of mononuclear cells from salivary glands showed that levels of Th2 cytokine-specific mRNA were higher in the immunized group than in the nonimmunized group. In addition, TSG DNA immunization resulted in the generation of antigen-specific CTL in spleen. These results indicate that TSG immunization with plasmid DNA may represent a genetic immunization strategy against infection by oral and pharyngeal pathogens that may invade local, mucosal surfaces.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531241      PMCID: PMC96967     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens.

Authors:  E Okada; S Sasaki; N Ishii; I Aoki; T Yasuda; K Nishioka; J Fukushima; J Miyazaki; B Wahren; K Okuda
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

Review 2.  DNA vaccines.

Authors:  H L Robinson; C A Torres
Journal:  Semin Immunol       Date:  1997-10       Impact factor: 11.130

3.  Induction of Th2 cytokine expression for p27-specific IgA B cell responses after targeted lymph node immunization with simian immunodeficiency virus antigens in rhesus macaques.

Authors:  S Kawabata; C J Miller; T Lehner; K Fujihashi; M Kubota; J R McGhee; K Imaoka; T Hiroi; H Kiyono
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

4.  Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site.

Authors:  B Wang; K Dang; M G Agadjanyan; V Srikantan; F Li; K E Ugen; J Boyer; M Merva; W V Williams; D B Weiner
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

Review 5.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells.

Authors:  K W Beagley; J H Eldridge; H Kiyono; M P Everson; W J Koopman; T Honjo; J R McGhee
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

7.  Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.

Authors:  D H Jones; S Corris; S McDonald; J C Clegg; G H Farrar
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

8.  Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques.

Authors:  T Lehner; Y Wang; M Cranage; L A Bergmeier; E Mitchell; L Tao; G Hall; M Dennis; N Cook; R Brookes; L Klavinskis; I Jones; C Doyle; R Ward
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

9.  Role of fimbriae in Porphyromonas gingivalis invasion of gingival epithelial cells.

Authors:  A Weinberg; C M Belton; Y Park; R J Lamont
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

10.  A role for fimbriae in Porphyromonas gingivalis invasion of oral epithelial cells.

Authors:  T Njoroge; R J Genco; H T Sojar; N Hamada; C A Genco
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

View more
  14 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice.

Authors:  S Kawabata; E Kunitomo; Y Terao; I Nakagawa; K Kikuchi; K Totsuka ; S Hamada
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  DNA-based adaptive immunity protect host from infection-associated periodontal bone resorption via recognition of Porphyromonas gingivalis virulence component.

Authors:  Xiaozhe Han; Karen B LaRosa; Toshihisa Kawai; Martin A Taubman
Journal:  Vaccine       Date:  2013-09-16       Impact factor: 3.641

6.  Arg-gingipain a DNA vaccine induces protective immunity against infection by Porphyromonas gingivalis in a murine model.

Authors:  H Yonezawa; K Ishihara; K Okuda
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Specific antibodies to Porphyromonas gingivalis Lys-gingipain by DNA vaccination inhibit bacterial binding to hemoglobin and protect mice from infection.

Authors:  M Kuboniwa; A Amano; S Shizukuishi; I Nakagawa; S Hamada
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  A focused salivary gland infection with attenuated MCMV: an animal model with prevention of pathology associated with systemic MCMV infection.

Authors:  Mark J Pilgrim; Laura Kasman; Jasvir Grewal; Mary E Bruorton; Phil Werner; Lucille London; Steven D London
Journal:  Exp Mol Pathol       Date:  2007-01-12       Impact factor: 3.362

9.  Salivary glands act as mucosal inductive sites via the formation of ectopic germinal centers after site-restricted MCMV infection.

Authors:  Jasvir S Grewal; Mark J Pilgrim; Suman Grewal; Laura Kasman; Phillip Werner; Mary E Bruorton; Steven D London; Lucille London
Journal:  FASEB J       Date:  2011-02-09       Impact factor: 5.191

10.  Expression and immunogenicity of Mycoplasma hyopneumoniae heat shock protein antigen P42 by DNA vaccination.

Authors:  Ya-Lei Chen; Shao-Ning Wang; Wen-Jen Yang; Yi-Jiun Chen; Hsi-Hsun Lin; David Shiuan
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.